



CHIA TAI ENTERPRISES INTERNATIONAL LIMITED
正大企業國際有限公司

Incorporated in Bermuda with limited liability • Stock Code : 3839
於百慕達註冊成立之有限公司 • 股份代號: 3839

INTERIM REPORT 2022 中期報告

Contents

目錄

- 2 Management Discussion and Analysis
管理層討論及分析
- 6 Report on Review of Interim Financial Report
中期財務報告之審閱報告
- 8 Consolidated Statement of Comprehensive Income
綜合全面收益表
- 10 Consolidated Statement of Financial Position
綜合財務狀況表
- 12 Consolidated Statement of Changes in Equity
綜合權益變動表
- 14 Condensed Consolidated Statement of Cash Flows
簡明綜合現金流量表
- 15 Notes to Interim Financial Report
中期財務報告附註
- 31 Other Information
其他資料
- 35 Corporate Information
公司資料

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

GROUP RESULTS

Chia Tai Enterprises International Limited (the “Company”) and its subsidiaries (the “Group”) have two lines of business: biochemical business and industrial business. The biochemical business focuses on chlortetracycline (“CTC”) and other related products, and is carried on by Group subsidiaries. This business segment accounts for all of the Group’s consolidated revenue. The industrial business comprises the Group’s interests in its joint venture ECI Metro Investment Co., Ltd. (together with its subsidiaries, “ECI Metro”) and its associate Zhanjiang Deni Vehicle Parts Co., Ltd. (together with its subsidiaries, “Zhanjiang Deni”). The results of the Group’s industrial business are incorporated in the consolidated statement of comprehensive income as share of profits and losses of joint venture and associate.

For the six months ended 30 June 2022 (“1H22”), the Group’s revenue increased by 28.2% to US\$81.21 million (for the six months ended 30 June 2021 (“1H21”): US\$63.37 million). Overall, gross profit margin declined by 2.3 percentage points year-on-year to 23.6% (1H21: 25.9%).

Loss attributable to shareholders of the Company was US\$4.98 million in 1H22, compared to profit attributable to shareholders of the Company of US\$6.72 million in 1H21. The turn from profit to loss was mainly due to share of profits and losses of ECI Metro deteriorating from a profit of US\$5.50 million in 1H21 to a loss of US\$5.34 million in 1H22.

Basic and diluted earnings per share were both negative 1.97 US cents in 1H22 (1H21: positive 2.65 US cents). The Board has resolved not to declare an interim dividend for the six months ended 30 June 2022 (1H21: Nil).

BUSINESS REVIEW

Biochemical

We generate a sizable portion of our revenue from the manufacture and sale of CTC products: CTC Premix and CTC HCL. CTC products are antibiotics used to prevent or cure animal diseases. In the past few years, we have been strategically broadening our product portfolio to cover other related veterinary products. Of these new offerings, some we manufacture and sell, and some we source and trade. The Group’s major customers include farms, pharmaceutical companies, trading companies and feed mills.

集團業績

正大企業國際有限公司(「本公司」)及其附屬公司(「本集團」)從事生化業務及工業業務。生化業務專注於金霉素及其他相關產品，並由本集團之附屬公司營運，乃佔本集團的所有綜合收入。工業業務包含本集團於易初明通投資有限公司(及其附屬公司，統稱「易初明通」)的合營企業權益及於湛江德利車輛部件有限公司(及其附屬公司，統稱「湛江德利」)的聯營公司權益。本集團工業業務的業績載列於綜合全面收益表內的應佔合營企業及聯營公司溢利及虧損。

截至二零二二年六月三十日止六個月(「二零二二年上半年」)，本集團的收入上升28.2%至8,121萬美元(截至二零二一年六月三十日止六個月(「二零二一年上半年」)：6,337萬美元)。整體毛利率按年下降2.3個百分點至23.6%(二零二一年上半年：25.9%)。

二零二二年上半年本公司股東應佔虧損為498萬美元，二零二一年上半年本公司股東應佔溢利則為672萬美元。轉盈為虧主要由於應佔易初明通溢利及虧損從二零二一年上半年盈利550萬美元惡化至二零二二年上半年虧損534萬美元。

每股基本及攤薄溢利為負1.97美仙(二零二一年上半年：正2.65美仙)。董事會決議截至二零二二年六月三十日止六個月不派付中期股息(二零二一年上半年：無)。

業務回顧

生化業務

我們的收入大部分來自製造及銷售金霉素產品：金霉素預混劑及鹽酸金霉素。金霉素產品為用作預防或治療動物疾病的抗生素。近年，我們一直在策略性地擴大我們的產品組合，以涵蓋其他相關的獸藥產品。在這些新產品中，一部分我們製造及銷售，一部分是我們採購和進行貿易的。本集團的主要客戶包括養殖場、製藥公司、貿易公司及飼料加工廠。

In 1H22, the Group's revenue from biochemical business increased by 28.2% to US\$81.21 million (1H21: US\$63.37 million). Revenue contribution from China, Americas, Asia Pacific (excluding China) and elsewhere was 40.5%, 24.3%, 20.4% and 14.8%, respectively.

For the period under review, despite multiple challenges at home and abroad, we recorded solid revenue growth mainly due to an increase in overseas sales. Despite logistical issues caused by the COVID-19 pandemic, we managed to increase revenue from our customers abroad via targeted marketing and promotion efforts. Sales to North America, in particular, increased significantly as we successfully sold CTC products to new customers.

In China, in response to the ban on the use of antibiotics as feed additives, the Group has successfully shifted its key CTC customers from feed mills to farms. However, during the period under review, soft animal protein prices led to a slowdown in farming activities. As a result, our customers from the farming sector cut their orders for CTC products. However, in response to the weakening demand for CTC products, we actively explored sales of other related veterinary products. These products generated new business for the Group and were the key revenue growth driver in China. As a result, overall domestic sales in China remained stable.

In 1H22, average selling price of CTC premix, our main revenue contributor, increased by 3.0% compared to 1H21 while average selling price of CTC HCL reduced by 3.2% year-on-year due to intensified pricing competition. However, rising raw material and energy costs put pressure on our profitability. Overall, gross profit margin reduced from 25.9% in 1H21 to 23.6% in 1H22.

Industrial

The Group's industrial business is conducted through ECI Metro and Zhanjiang Deni.

ECI Metro is principally engaged in the sale, leasing and servicing of Caterpillar machinery equipment in the western part of China. According to the National Bureau of Statistics of the People's Republic of China, fixed-asset investment growth in China was 6.1% in 1H22, and that in the western part of China was 8.0%. Within fixed-asset investment, infrastructure investment in road transport and railway transport fell by 0.2% and 4.4%, respectively, when compared to 1H21. The sluggish industry environment and intensified competition from domestic manufacturers added pressure to both sales and margins. For the six months ended 30 June 2022, our share of losses of joint venture was US\$5.34 million, compared to share of profits of US\$5.50 million in 1H21.

二零二二年上半年，本集團生化業務的收入上升28.2%至8,121萬美元（二零二一年上半年：6,337萬美元）。其中，來自中國、美洲、亞太地區（不包括中國）及其他地方的收入分別佔40.5%，24.3%，20.4%及14.8%。

回顧期內，儘管在國內外面臨多重挑戰，但我們仍錄得穩健的收入增長，主要由於海外銷售增加。儘管新型冠狀病毒疫情引起物流問題，我們通過針對性的營銷和促銷工作成功增加來自海外客戶的收入，我們成功銷售金霉素產品予新客戶導致對北美的銷售增加尤其顯著。

在中國，以應對禁止使用抗生素於飼料添加劑，本集團成功地將主要的金霉素客戶從飼料加工廠轉移至養殖場。回顧期內，因動物蛋白價格疲弱導致養殖活動放緩。因此，我們的養殖業客戶減少對金霉素產品的訂單。然而，為應對金霉素產品的疲軟需求，我們積極開拓其他相關獸藥產品的銷售。這些產品為本集團帶來新的業務，是中國收入的主要增長點。因此，中國整體國內銷售保持穩定。

二零二二年上半年，我們的主要收入來源金霉素預混劑的平均銷售價格與二零二一年上半年相比上漲3.0%，而鹽酸金霉素的平均銷售價格，因價格競爭加劇則按年下降了3.2%。然而，原材料和能源成本的上漲對我們的盈利能力構成壓力。總體而言，毛利率從二零二一年上半年的25.9%下降至二零二二年上半年的23.6%。

工業業務

本集團的工業業務透過易初明通及湛江德利經營。

易初明通主要在中國西部從事卡特彼勒機械設備的銷售、租賃及維修服務。根據中華人民共和國國家統計局統計，二零二二年上半年中國固定資產投資增長6.1%，其中中國西部錄得8.0%的增長。固定資產投資中的公路運輸和鐵路運輸的基礎設施投資與二零二一年上半年相比分別下降0.2%及4.4%。行業市場環境低迷，加上來自國內生產商的競爭加劇，增加了銷售和利潤率的壓力。截至二零二二年六月三十日止六個月，應佔合營企業虧損為534萬美元，而二零二一年上半年應佔合營企業溢利則為550萬美元。

Zhanjiang Deni is principally engaged in the manufacture and sale of automotive parts, which are mainly sold to automobile and motorcycle manufacturers. According to the China Association of Automobile Manufacturers, automobile sales was 6.6% lower than that in 1H21; and according to the China Chamber of Commerce for Motorcycle, motorcycle sales in 1H22 decreased by 14.3% year-on-year. In response to market challenges, measures have been taken to bring down operating costs. As a result, our share of profits of associate increased to US\$1.11 million (1H21: US\$0.70 million) for the six months ended 30 June 2022.

OUTLOOK

Looking forward, the Group continues to face multiple challenges. For our biochemical business, the COVID-19 pandemic poses continuous pressure to the economy in China and abroad. Meanwhile, the sagging farming market reduces the demand from our customers. These factors continue to bring uncertainties to our biochemical business. For our industrial business, fixed-asset investment growth in China in the remainder of 2022 is expected to hover at a low level and competition is likely to intensify. Overall, we expect the rest of 2022 to be difficult.

LIQUIDITY AND FINANCIAL RESOURCES

As at 30 June 2022, the Group had total assets of US\$351.7 million, a decrease of 3.7% as compared to US\$365.2 million as at 31 December 2021.

Net debt (30 June 2022: US\$15.5 million, 31 December 2021: US\$11.5 million) to equity ratio (defined as total bank borrowings minus cash divided by total equity) was 0.06 as compared to 0.04 as at 31 December 2021.

All the borrowings of the Group are denominated in Renminbi (“RMB”) as at 30 June 2022 and 31 December 2021.

As at 30 June 2022, the Group’s fixed interest rate bank borrowings amounted to US\$26.6 million (31 December 2021: US\$20.9 million).

All domestic sales in mainland China are transacted in RMB and export sales are transacted in foreign currencies. The Group monitors exchange rate movements and determines appropriate hedging activities when necessary.

湛江德利專注製造及銷售汽車零件，主要出售予汽車及摩托車製造商。根據中國汽車工業協會統計，汽車銷售量較二零二一年上半年下降6.6%，而根據中國摩托車商會統計，摩托車銷售量則按年下降14.3%。為應對市場挑戰，我們已採取措施以減低營運成本。因此，截止二零二二年六月三十日止六個月，應佔聯營公司溢利上升至111萬美元（二零二一年上半年：70萬美元）。

展望

展望未來，本集團繼續面臨各種挑戰。對於我們的生化業務，新型冠狀病毒疫情對國內及國外經濟帶來持續的壓力。同時，低迷的養殖市場減少了我們客戶的需求。這些因素繼續給我們的生化業務帶來不確定性。至於我們的工業業務，預計二零二二年餘下時間中國固定資產投資增長將在低位徘徊，而行業競爭可能更為激烈。總體而言，我們預期二零二二年餘下時間將會很艱難。

資金流動性及財政資源

於二零二二年六月三十日，本集團之總資產為3.52億美元，較二零二一年十二月三十一日之3.65億美元，減少3.7%。

淨債務（二零二二年六月三十日：1,550萬美元，二零二一年十二月三十一日：1,150萬美元）對權益比率（定義為銀行借款減現金後除以權益總額）為0.06，相對二零二一年十二月三十一日則為0.04。

本集團於二零二二年六月三十日及二零二一年十二月三十一日的借款全部按人民幣作為單位。

於二零二二年六月三十日，本集團按固定利率計息之借款為2,660萬美元（二零二一年十二月三十一日：2,090萬美元）。

於中國大陸所有國內銷售均以人民幣計算，而出口之銷售則以外幣計算。本集團監控外匯變動，必要時考慮適當的對沖活動。

CAPITAL STRUCTURE

The Group finances its working capital requirements through a combination of funds generated from operations and borrowings. The Group had cash and cash equivalents of US\$28.3 million as at 30 June 2022, a decrease of US\$2.8 million compared to 31 December 2021.

CHARGES ON GROUP ASSETS

As at 30 June 2022, out of the total borrowings of US\$43.8 million (31 December 2021: US\$42.6 million) obtained by the Group, US\$20.2 million (31 December 2021: US\$18.9 million) was secured, which accounted for 46.2% (31 December 2021: 44.4%) of the total borrowings. Certain of the Group's property, plant and equipment and land lease prepayments with an aggregate net book value of US\$14.4 million (31 December 2021: US\$10.8 million) were pledged as security.

CONTINGENT LIABILITIES

As at 30 June 2022, the Group did not have any significant contingent liabilities.

SIGNIFICANT INVESTMENTS HELD, MATERIAL ACQUISITIONS AND DISPOSALS

Save for those disclosed in this interim report, there were no other significant investments held nor material acquisitions or disposals during the period.

EMPLOYEE AND REMUNERATION POLICIES

As at 30 June 2022, the Group employed around 1,000 employees in mainland China and Hong Kong. The Group remunerates its employees based on their performance, experience and prevailing market conditions while performance bonuses are granted on a discretionary basis. Other employee benefits include, for example, medical insurance and training.

資本結構

本集團透過營運資金及借款應付其流動資金需求。於二零二二年六月三十日，本集團持有現金及現金等價物2,830萬美元，較二零二一年十二月三十一日減少280萬美元。

本集團資產抵押

於二零二二年六月三十日，本集團總借款為4,380萬美元（二零二一年十二月三十一日：4,260萬美元），其中2,020萬美元（二零二一年十二月三十一日：1,890萬美元）借款需提供資產抵押，佔借款總額之46.2%（二零二一年十二月三十一日：44.4%）。本集團若干物業、廠房及設備及預付土地租賃費已用作抵押，賬面淨額合共1,440萬美元（二零二一年十二月三十一日：1,080萬美元）。

或有負債

本集團於二零二二年六月三十日並沒有任何重大或有負債。

持有的重大投資、重大收購及出售

除本中期報告所披露外，本集團在期內沒有持有任何其他重大投資，亦沒有進行任何重大收購或出售。

僱員及酬金政策

於二零二二年六月三十日，本集團於中國大陸及香港共聘用約1,000名僱員。本集團根據僱員的表現、經驗及現行的市場水平，釐訂其薪津，並酌情授予花紅。其他僱員福利包括例如：醫療保險及培訓。

REPORT ON REVIEW OF INTERIM FINANCIAL REPORT



Review report to the board of directors of
Chia Tai Enterprises International Limited
(Incorporated in Bermuda with limited liability)

Introduction

We have reviewed the interim financial report set out on pages 8 to 30 which comprises the consolidated statement of financial position of Chia Tai Enterprises International Limited (the “Company”) and its subsidiaries (together, the “Group”) as of 30 June 2022 and the related consolidated statement of comprehensive income, consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six month period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34, *Interim Financial Reporting*, issued by the International Accounting Standards Board. The directors are responsible for the presentation of the interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

中期財務報告之審閱報告

致正大企業國際有限公司董事會之審閱報告

(於百慕達註冊成立之有限公司)

緒言

我們已審閱第8至30頁所載之中期財務報告，當中包括正大企業國際有限公司（「貴公司」）及其附屬公司（以下統稱「貴集團」）於二零二二年六月三十日的綜合財務狀況表與截至該日止六個月期間的相關綜合全面收益表、綜合權益變動表和簡明綜合現金流量表及附註解釋。香港聯合交易所有限公司證券上市規則規定，中期財務報告之編製必須符合當中有關條文，以及由國際會計準則委員會頒佈的國際會計準則第34號*中期財務報告*。董事須負責根據國際會計準則第34號編制及呈報中期財務報告。

我們的責任是根據我們的審閱對中期財務報告作出結論，並按照我們雙方所協定之委聘條款僅向全體董事會報告，且不可作其他用途。我們不會就本報告的內容，對任何其他人士負責或承擔任何責任。

審閱範圍

我們已根據香港會計師公會頒佈的香港審閱工作準則第2410號*獨立核數師對中期財務信息的審閱*進行審閱。審閱中期財務報告包括向主要負責財務和會計事務之人員作出查詢，並應用分析性和其他審閱程序。由於審閱範圍遠少於根據香港審核準則進行審核之範圍，故不能保證我們會知悉在審核中可能發現之所有重大事項。因此，我們不會發表審核意見。

**REPORT ON REVIEW OF INTERIM
FINANCIAL REPORT (CONTINUED)**

中期財務報告之審閱報告(續)

Conclusion

結論

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2022 is not prepared, in all material respects, in accordance with International Accounting Standard 34, *Interim Financial Reporting*.

根據我們的審閱，我們並無發現任何事項令我們相信截至二零二二年六月三十日之中期財務報告在各重大方面未有根據國際會計準則第34號中期財務報告編製。

KPMG

Certified Public Accountants
8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

畢馬威會計師事務所

執業會計師
香港中環
遮打道10號
太子大廈8樓

10 August 2022

二零二二年八月十日

**CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME**
綜合全面收益表

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
		Note 附註	
REVENUE	收入	5	81,211
Cost of sales	銷售成本		(62,084)
Gross profit			19,127
	毛利		16,414
Other income, net	其他收入淨額	6	24
Selling and distribution costs	銷售及分銷成本		(6,917)
General and administrative expenses	行政及管理費用		(10,465)
Finance costs	財務成本	7	(433)
Share of profits and losses of:	應佔溢利及虧損：		
Joint venture	合營企業		(5,340)
Associate	聯營公司		1,113
(LOSS)/PROFIT BEFORE TAX	除稅前(虧損)/溢利	8	(2,891)
Income tax	所得稅	9	(1,049)
(LOSS)/PROFIT FOR THE PERIOD	期內(虧損)溢利		(3,940)
(Loss)/profit attributable to:	(虧損)/溢利歸屬予：		
Shareholders of the Company	本公司股東		(4,984)
Non-controlling interests	非控制性權益		1,044
			(3,940)
			7,702
			US cents
			美仙
(LOSSES)/EARNINGS PER SHARE	本公司股東應佔之		
ATTRIBUTABLE TO SHAREHOLDERS OF	每股(虧損)/溢利		
THE COMPANY		11	
Basic and diluted	基本及攤薄		(1.97)
			2.65

**CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME (CONTINUED)****綜合全面收益表(續)**

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
(LOSS)/PROFIT FOR THE PERIOD	期內(虧損)/溢利	(3,940)	7,702
OTHER COMPREHENSIVE INCOME	其他全面收益		
Items that may be reclassified subsequently to profit or loss:	其後可能會重新分類至損益之項目：		
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	(4,214)	828
Share of other comprehensive income of:	應佔其他全面收益：		
Joint venture	合營企業	(6,144)	1,361
Associate	聯營公司	(1,126)	219
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	期內其他全面收益	(11,484)	2,408
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額	(15,424)	10,110
Total comprehensive income attributable to:	全面收益總額歸屬予：		
Shareholders of the Company	本公司股東	(15,199)	8,890
Non-controlling interests	非控制性權益	(225)	1,220
		(15,424)	10,110

**CONSOLIDATED STATEMENT OF
FINANCIAL POSITION**
綜合財務狀況表

			30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日
	Note 附註		US\$'000 美元千元 (Unaudited) (未經審核)	US\$'000 美元千元 (Audited) (經審核)
NON-CURRENT ASSETS		非流動資產		
Property, plant and equipment	12	物業、廠房及設備	91,038	92,586
Land lease prepayments		預付土地租賃費	5,391	5,755
Investments in joint venture		於合營企業的投資	109,075	120,559
Investments in associate		於聯營公司的投資	19,504	21,838
Other non-current assets		其他非流動資產	253	-
Total non-current assets		總非流動資產	225,261	240,738
CURRENT ASSETS		流動資產		
Inventories		存貨	38,484	36,070
Trade and bills receivables	13	應收貿易賬款及票據	43,539	39,559
Prepayments, deposits and other receivables		預付賬款、按金及其他應收賬款	16,089	17,756
Cash and cash equivalents		現金及現金等價物	28,298	31,093
Total current assets		總流動資產	126,410	124,478
CURRENT LIABILITIES		流動負債		
Trade payables	14	應付貿易賬款	17,666	13,279
Other payables and accruals		其他應付賬款及預提費用	16,091	14,250
Bank borrowings		銀行借款	32,427	26,325
Income tax payables		應付所得稅	7,096	5,301
Total current liabilities		總流動負債	73,280	59,155
NET CURRENT ASSETS		淨流動資產	53,130	65,323
TOTAL ASSETS LESS CURRENT LIABILITIES		總資產減流動負債	278,391	306,061

**CONSOLIDATED STATEMENT OF
FINANCIAL POSITION (CONTINUED)**
綜合財務狀況表(續)

			30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日
		Note 附註	US\$'000 美元千元 (Unaudited) (未經審核)	US\$'000 美元千元 (Audited) (經審核)
NON-CURRENT LIABILITIES	非流動負債			
Bank borrowings	銀行借款		11,401	16,287
Other non-current liabilities	其他非流動負債		2,312	2,370
Deferred tax liabilities	遞延稅項負債		2,613	3,881
Total non-current liabilities	總非流動負債		16,326	22,538
NET ASSETS	資產淨值		262,065	283,523
EQUITY	權益			
Equity attributable to shareholders of the Company	本公司股東應佔權益			
Issued capital	已發行股本	15	25,333	25,333
Reserves	儲備		212,527	227,726
			237,860	253,059
Non-controlling interests	非控制性權益		24,205	30,464
TOTAL EQUITY	權益總額		262,065	283,523

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 綜合權益變動表

Six months ended 30 June 2022

截至二零二二年六月三十日止六個月

		Attributable to shareholders of the Company 本公司股東應佔							
		Issued capital 已發行股本	Capital reserve 資本儲備	PRC reserve funds 中國儲備基金	Exchange fluctuation reserve 外匯波動儲備	Retained profits 未分配利潤	Total	Non-controlling interests 非控制性權益	Total equity 權益總額
		US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元
		(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)
At 1 January 2022	於二零二二年一月一日	25,333	10,845	17,989	16,793	182,099	253,059	30,464	283,523
(Loss)/profit for the period	期內(虧損)/溢利					(4,984)	(4,984)	1,044	(3,940)
Other comprehensive income for the period:	期內其他全面收益:								
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	-	-	-	(2,945)	-	(2,945)	(1,269)	(4,214)
Share of other comprehensive income of:	應佔其他全面收益:								
Joint venture	合營企業	-	-	-	(6,144)	-	(6,144)	-	(6,144)
Associate	聯營公司	-	-	-	(1,126)	-	(1,126)	-	(1,126)
Total comprehensive income for the period	期內全面收益總額	-	-	-	(10,215)	(4,984)	(15,199)	(225)	(15,424)
Dividend declared to non-controlling equity holders	宣派予非控制性權益股東股息	-	-	-	-	-	-	(6,034)	(6,034)
At 30 June 2022	於二零二二年六月三十日	25,333	10,845	17,989	6,578	177,115	237,860	24,205	262,065

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED) 綜合權益變動表(續)

Six months ended 30 June 2021

截至二零二一年六月三十日止六個月

		Attributable to shareholders of the Company 本公司股東應佔						Non-	Total
		Issued capital 已發行股本	Capital reserve 資本儲備	PRC reserve funds 中國儲備基金	Exchange fluctuation reserve 外匯波動儲備	Retained profits 未分配利潤	Total	controlling interests 非控制性權益	equity 權益總額
		US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元	US\$'000 美元千元
		(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)	(Unaudited) (未經審核)
At 1 January 2021	於二零二一年一月一日	25,333	10,845	17,427	11,297	163,097	227,999	22,611	250,610
Profit for the period	期內溢利	-	-	-	-	6,724	6,724	978	7,702
Other comprehensive income for the period:	期內其他全面收益：								
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	-	-	-	586	-	586	242	828
Share of other comprehensive income of:	應佔其他全面收益：								
Joint venture	合營企業	-	-	-	1,361	-	1,361	-	1,361
Associate	聯營公司	-	-	-	219	-	219	-	219
Total comprehensive income for the period	期內全面收益總額	-	-	-	2,166	6,724	8,890	1,220	10,110
At 30 June 2021	於二零二一年六月三十日	25,333	10,845	17,427	13,463	169,821	236,889	23,831	260,720

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS 簡明綜合現金流量表

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動之現金流量		
Cash generated from/(used in) operations	經營產生/(所用)之現金	3,037	(9,625)
Interest paid	已付利息	(1,018)	(579)
Income tax paid	已付所得稅	(82)	(425)
Net cash flows generated from/(used in) operating activities	經營活動所得/(所用)之現金流量淨額	1,937	(10,629)
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動之現金流量		
Purchases of property, plant and equipment	購買物業、廠房及設備	(6,214)	(4,251)
Other cash flows arising from investing activities	其他源自投資活動之現金流量	(1,552)	(6,193)
Net cash flows used in investing activities	投資活動所用之現金流量淨額	(7,766)	(10,444)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動之現金流量		
Proceeds from bank borrowings	銀行借款所得款項	18,722	16,600
Repayment of bank borrowings	償還銀行借款	(15,208)	(1,576)
Net cash flows generated from financing activities	融資活動所得之現金流量淨額	3,514	15,024
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物減少淨額	(2,315)	(6,049)
Cash and cash equivalents at beginning of period	期初之現金及現金等價物	31,093	32,258
Effect of foreign exchange rate changes, net	外匯率變動之影響淨額	(480)	122
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末之現金及現金等價物	28,298	26,331

NOTES TO INTERIM FINANCIAL REPORT**中期財務報告附註****1. GENERAL INFORMATION**

Chia Tai Enterprises International Limited (the “Company”) is a limited liability company incorporated in Bermuda. The Company and its subsidiaries hereinafter are collectively referred to as the “Group”. The Group and its joint venture and associate are principally involved in (i) manufacturing and/or sale of chlortetracycline and other related products; (ii) trading of machinery; and (iii) manufacturing and sale of automotive parts respectively.

At 30 June 2022, the directors consider the immediate holding company of the Company to be Charoen Pokphand Foods Public Company Limited (“CPF”), which is incorporated in the Kingdom of Thailand and shares of which are listed on the Stock Exchange of Thailand, and remains to be as such as at the date of approval of these financial statements. CPF is a significantly owned company of Charoen Pokphand Group Company Limited (“CPG”), which is incorporated in the Kingdom of Thailand.

2. BASIS OF PREPARATION

This interim financial report is unaudited and has been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting* issued by the International Accounting Standards Board (the “IASB”) and the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The accounting policies and the basis of preparation adopted in the preparation of this interim financial report are consistent with those adopted in the annual financial statements for the year ended 31 December 2021, which were prepared in accordance with International Financial Reporting Standards (“IFRSs”) (which include all IFRSs, IASs and Interpretations) issued by the IASB, except for the accounting policy changes as set out in note 3 below. This interim financial report should be read in conjunction with the annual financial statements for the year ended 31 December 2021.

1. 一般資料

正大企業國際有限公司(「本公司」)為一家於百慕達註冊成立之有限公司。本公司及其附屬公司以下統稱為「本集團」。本集團及其合營企業及聯營公司主要分別從事(i)製造及／或銷售金霉素及其他相關產品；(ii)機械設備貿易；及(iii)產銷汽車零部件。

於二零二二年六月三十日，董事認為，本公司之直接控股公司為於泰國註冊成立的Charoen Pokphand Foods Public Company Limited(「CPF」)，其股份於泰國證券交易所上市，並於截至本財務報告獲批當日仍然為本公司的直接控股公司。CPF為一家於泰國註冊成立的Charoen Pokphand Group Company Limited(「CPG」)重大持有之公司。

2. 編製基準

此中期財務報告乃未經審核及按照國際會計準則委員會頒佈之國際會計準則(「國際會計準則」)第34號*中期財務報告*及香港聯合交易所有限公司證券上市規則(「上市規則」)適用之有關披露規定而編製。

除載列於以下附註3之會計政策更改外，此中期財務報告之會計政策及編製基準與截至二零二一年十二月三十一日止年度之年度財務報表所採用之會計政策及編製基準一致，乃按照國際會計準則委員會頒佈之國際財務報告準則(「國際財務報告準則」)(亦包括所有國際財務報告準則、國際會計準則及詮釋)而編製。此中期財務報告應與截至二零二一年十二月三十一日止年度之年度財務報表一併閱讀。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

3. CHANGES IN ACCOUNTING POLICY AND DISCLOSURES

The IASB has issued a number of new standards, amendments to IFRSs and interpretation that are first effective for the current interim period. Of these, the following amendments may be relevant to the Group:

Annual improvements to IFRSs 2018-2020 cycle	Amendments to IFRS 1 <i>First-time adoption of international financial reporting standards</i> , IFRS 9 <i>Financial instruments</i> , IFRS 16 <i>Leases</i> and IAS 41 <i>Agriculture</i>
Amendments to IFRS 3	Amendments to IFRS 3 <i>Reference to the conceptual framework</i>
Amendments to IAS 16	Amendments to IAS 16 <i>Property, plant and equipment: proceeds before intended use</i>
Amendments to IAS 37	Amendments IAS 37 <i>Onerous contracts – cost of fulfilling a contract</i>

None of the new standard, amendment or interpretation have had a significant financial effect to the Group. The Group has not applied any new standard, amendment or interpretation that is not yet effective for the current period.

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments:

- the biochemical segment is principally engaged in the manufacture and/or sale of chlortetracycline and other related products; and
- the industrial segment is principally engaged in the trading of machinery and the manufacture and sale of automotive parts, through the Group's joint venture and associate.

3. 會計政策及披露之更改

國際會計準則委員會已頒佈若干國際財務報告準則的新準則、修訂及詮釋，並於本中期首次生效。下列為當中可能與本集團有關之修訂：

國際財務報告準則 2018-2020週期年度改進	修訂國際財務報告準則第1號 <i>首次採用國際財務報告準則</i> 、修訂國際財務報告準則第9號 <i>金融工具</i> 、修訂國際財務報告準則第16號 <i>租賃</i> 、修訂國際會計準則第41號 <i>農業</i>
國際財務報告準則第3號修訂	修訂國際財務報告準則第3號 <i>引用國際財務報告準則概念框架</i>
國際會計準則第16號的修訂	修訂國際會計準則第16號 <i>物業、廠房及設備：達到預定用途前所獲收入</i>
國際會計準則第37號的修訂	修訂國際會計準則第37號 <i>虧損合同－履行合同的成本</i>

採納國際財務報告準則的新準則、修訂及詮釋不會對本集團構成重大財務影響。本集團於本期內並無採納任何尚未生效的新準則、修訂或詮釋。

4. 經營分類資料

按管理所需，本集團將業務按產品及服務分成兩個可呈報經營分類：

- 生化分類代表主要製造及／或銷售金霉素及其他相關產品；及
- 工業分類代表主要從事機械設備貿易及產銷汽車零部件（透過本集團之合營企業及聯營公司）。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit/(loss), which is a measure of adjusted profit/(loss) before tax. The adjusted profit/(loss) before tax is measured consistently with the Group's profit/(loss) before tax except that bank interest income, finance costs and items not specifically attributed to individual segments, such as head office or corporate administration expenses are excluded from such measurements.

Segment assets exclude unallocated corporate assets. Unallocated corporate assets include cash and cash equivalents, income tax receivable and other assets that are managed on a group basis.

Segment liabilities exclude unallocated corporate liabilities. Unallocated corporate liabilities include bank borrowings, income tax payables and deferred tax liabilities and other liabilities that are managed on a group basis.

All revenue from contracts with customers is recognised at the point in time when our customer obtains control of the promised goods, i.e. when products are delivered to the customers' premises for domestic sales or in accordance with the terms and conditions of sale for export sales. The major product line of the Group is the manufacture and/or sale of chlortetracycline and other related products in biochemical segment as disclosed in note 4(a).

Disaggregation of revenue from contracts with customers by geographical location of customers is disclosed in note 4(b)(i).

4. 經營分類資料(續)

管理層會獨立監察本集團經營分類之業績而作出資源分配之決定及評定其表現。分類表現評估乃根據可呈報分類之溢利／(虧損)，即以經調整稅前溢利／(虧損)計算。經調整稅前溢利／(虧損)之計算與本集團稅前溢利／(虧損)之計算一致，除銀行利息收入、財務成本及不屬於個別分類之項目，如總部或企業行政開支不包括在其計算當中。

分類資產不包括未分配企業資產。未分配企業資產包括現金及現金等價物、預付所得稅及其他在集團層面管理之資產。

分類負債不包括未分配企業負債。未分配企業負債包括銀行借款、應付所得稅、遞延稅項負債及其他在集團層面管理之負債。

所有源自與客戶的合約收入於客戶獲得承諾產品之控制權之時點確認，即於產品送達客戶場地時(國內銷售)或按照銷售條款和條件(出口銷售)。本集團主要的產品線為生化分類之製造及／或銷售金霉素及其他相關產品，如附註4(a)披露。

源自與客戶的合約收入按客戶所在地分類，並於附註4(b)(i)披露。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments

(a) 可呈報經營分類

The following tables present revenue, profit or loss and certain assets, liabilities and expenditure information for the Group's reportable operating segments during the period.

以下報表為本集團各可呈報經營分類於期內之收入、損益及若干資產、負債及開支資料。

Six months ended 30 June 2022

截至二零二二年六月三十日止六個月

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	81,211	-	81,211
Segment results	分類業績			
The Group	本集團	3,453	(804)	2,649
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	-	(5,340)	(5,340)
Associate	聯營公司	-	1,113	1,113
		<u>3,453</u>	<u>(5,031)</u>	<u>(1,578)</u>
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			68
Finance costs	財務費用			(433)
Unallocated head office and corporate expenses	未分配總部及企業開支			(948)
Loss before tax	除稅前虧損			<u>(2,891)</u>
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	3,569	-	3,569
Capital expenditure*	資本開支*	6,800	-	6,800

* Including additions to property, plant and equipment.

* 包括物業、廠房及設備之新增。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 30 June 2022

於二零二二年六月三十日

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment assets	分類資產	187,582	135,768	323,350
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			28,321
Total assets	總資產			351,671
Segment liabilities	分類負債	35,243	18	35,261
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			54,345
Total liabilities	總負債			89,606
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	-	109,075	109,075
Investments in associate	於聯營公司的投資	-	19,504	19,504

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

Six months ended 30 June 2021

截至二零二一年六月三十日止六個月

		Biochemical operations 生化業務 US\$'000 美元千元 (Unaudited) (未經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	63,369	–	63,369
Segment results	分類業績			
The Group	本集團	4,338	(548)	3,790
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	–	5,502	5,502
Associate	聯營公司	–	703	703
		4,338	5,657	9,995
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			55
Finance costs	財務費用			(170)
Unallocated head office and corporate expenses	未分配總部及企業開支			(1,081)
Profit before tax	除稅前溢利			8,799
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	3,595	9	3,604
Capital expenditure*	資本開支*	4,660	–	4,660

* Including additions to property, plant and equipment.

* 包括物業、廠房及設備之新增。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 31 December 2021

於二零二一年十二月三十一日

		Biochemical operations 生化業務 US\$'000 美元千元 (Audited) (經審核)	Industrial operations 工業業務 US\$'000 美元千元 (Audited) (經審核)	Total 總額 US\$'000 美元千元 (Audited) (經審核)
Segment assets	分類資產	186,447	147,582	334,029
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			31,187
Total assets	總資產			365,216
Segment liabilities	分類負債	29,123	39	29,162
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			52,531
Total liabilities	總負債			81,693
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	–	120,559	120,559
Investments in associate	於聯營公司的投資	–	21,838	21,838

(b) Geographical information

(b) 地區資料

(i) Revenue from external customers

(i) 來自外來客戶之收入

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
Mainland China	中國大陸	32,905	32,069
Americas	美洲	19,720	12,634
Asia Pacific (excluding mainland China)	亞太地區(不包括中國大陸)	16,560	13,424
Elsewhere	其他地方	12,026	5,242
		81,211	63,369

The revenue information shown above is based on the location of customers.

上列收入資料乃按客戶所在地分類。

(ii) Non-current assets

(ii) 非流動資產

At 30 June 2022, 99% (31 December 2021: 99%) of the Group's non-current assets are located in mainland China.

於二零二二年六月三十日，本集團99% (二零二一年十二月三十一日：99%) 之非流動資產均位於中國大陸。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

5. REVENUE

Revenue represents the aggregate of the invoiced value of goods sold, net of value-added tax and government surcharges, and after allowances for goods returned and trade discounts recognised within the scope of IFRS 15. All of the Group's revenue is from the biochemical segment.

6. OTHER INCOME, NET

An analysis of other income, net is as follows:

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
Bank interest income	銀行利息收入	68	55
Government grants	政府補助	644	658
Foreign exchange differences, net	外幣折算差異淨額	(906)	17
Others	其他	218	113
		24	843

7. FINANCE COSTS

7. 財務成本

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
Interest expense on bank borrowings	銀行借款之利息費用	1,018	578
Less: interest expense capitalised*	減:利息費用資本化*	(585)	(408)
		433	170

* Interest expense was capitalised at interest rate based on the respective loan facilities of 3.5%-5.4% per annum (six months ended 30 June 2021: 3.9%-5.4% per annum).

* 利息費用資本化乃按各貸款協議之年利率3.5%至5.4% (二零二一年六月三十日止六個月: 年利率3.9%至5.4%) 計算。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

8. (LOSS)/PROFIT BEFORE TAX

The Group's (loss)/profit before tax is arrived at after charging:

Cost of inventories sold	已出售存貨成本	62,084	46,955
Depreciation of property, plant and equipment	物業、廠房及設備之折舊	3,497	3,529
Amortisation of land lease prepayments	預付土地租賃費之攤銷	72	75

9. INCOME TAX

No provision for Hong Kong profits tax has been made for the period as the Group did not generate any assessable profits in Hong Kong during the current period (six months ended 30 June 2021: nil).

Subsidiaries operating in the People's Republic of China ("PRC") are subject to income tax at the rate of 25% (six months ended 30 June 2021: 25%) on their taxable income according to the PRC corporate income tax laws. In accordance with the relevant tax rules and regulations in the PRC, certain subsidiaries of the Group in the PRC enjoy income tax exemptions or reductions.

Current – the PRC	本期 – 中國	2,474	774
Charge for the period	期內支出	(183)	24
(Over)/under-provision in prior years	往年(多)/少計提	(1,242)	299
Deferred	遞延		

Total tax expense for the period

期內稅項總支出

1,049

1,097

10. INTERIM DIVIDEND

The Board has resolved not to declare an interim dividend for the six months ended 30 June 2022 (six months ended 30 June 2021: nil).

8. 除稅前(虧損)/溢利

本集團除稅前(虧損)/溢利經扣除下列各項：

Six months ended 30 June	
截至六月三十日止六個月	
2022	2021
二零二二年	二零二一年
US\$'000	US\$'000
美元千元	美元千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

9. 所得稅

本集團於本期內未有在香港賺取任何應課稅收入，所以未於期內作香港利得稅撥備(截至二零二一年六月三十日止六個月：無)。

根據中國企業所得稅稅例，於中華人民共和國(「中國」)經營之附屬公司需就其應課稅收入按稅率25%(截至二零二一年六月三十日止六個月：25%)繳交所得稅。根據中國之相關稅務守則及法例，本集團於中國之若干附屬公司享有豁免或減收所得稅之優惠。

Six months ended 30 June	
截至六月三十日止六個月	
2022	2021
二零二二年	二零二一年
US\$'000	US\$'000
美元千元	美元千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Current – the PRC	本期 – 中國	2,474	774
Charge for the period	期內支出	(183)	24
(Over)/under-provision in prior years	往年(多)/少計提	(1,242)	299
Deferred	遞延		

Total tax expense for the period

期內稅項總支出

1,049

1,097

10. 中期股息

董事會決議截至二零二二年六月三十日止六個月不派付中期股息(截至二零二一年六月三十日止六個月：無)。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

11. (LOSSES)/EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic (losses)/earnings per share is based on the (loss)/profit for the period attributable to shareholders of the Company and the weighted average number of ordinary shares and convertible preference shares in issue during the period.

The calculation of basic (losses)/earnings per share is based on the following data:

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
(Losses)/earnings	(虧損)／溢利		
(Loss)/profit for the period attributable to shareholders of the Company, used in the basic (losses)/earnings per share calculation	用於計算每股基本(虧損)／溢利之本公司股東本期應佔(虧損)／溢利	(4,984)	6,724
		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
Shares	股份		
Weighted average number of ordinary shares and convertible preference shares in issue during the period, used in the basic (losses)/earnings per share calculation	用於計算每股基本(虧損)／溢利之期內已發行之普通股及可換股優先股加權平均數	253,329,087	253,329,087

As there were no potential dilutive ordinary shares during the six months ended 30 June 2022 and 2021, the amount of diluted (losses)/earnings per share is equal to basic (losses)/earnings per share.

每股基本(虧損)／溢利金額之計算乃根據本公司股東應佔期內(虧損)／溢利及期內已發行之普通股及可換股優先股加權平均數。

每股基本(虧損)／溢利乃根據以下數據計算：

於二零二二及二零二一年六月三十日止六個月期間並無潛在攤薄普通股，故每股攤薄(虧損)／溢利相等於每股基本(虧損)／溢利。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

12. PROPERTY, PLANT AND EQUIPMENT

12. 物業、廠房及設備

		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Audited) (經審核)
At 1 January:	於一月一日：		
Cost	成本	154,060	157,247
Accumulated depreciation and impairment	累計折舊及減值	(61,474)	(68,595)
Net carrying amount	賬面淨值	92,586	88,652
Net carrying amount:	賬面淨值：		
At 1 January	於一月一日	92,586	88,652
Additions	添置	6,800	13,515
Depreciation provided during the period	期內計提折舊	(3,497)	(7,409)
Disposals	出售	-	(4,577)
Exchange realignment	匯兌調整	(4,851)	2,405
At 30 June/31 December	於六月三十日／十二月三十一日	91,038	92,586
At 30 June/31 December:	於六月三十日／十二月三十一日：		
Cost	成本	152,745	154,060
Accumulated depreciation and impairment	累計折舊及減值	(61,707)	(61,474)
Net carrying amount	賬面淨值	91,038	92,586

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

13. TRADE AND BILLS RECEIVABLES

Depending on the requirements of the market and business, the Group may extend credit to its customers. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by management and interest may be charged by the Group for overdue trade receivable at rates determined by the Group with reference to market practice. In the opinion of the directors, there is no significant concentration of credit risk. An aging analysis of the Group's trade and bills receivables, based on the date of delivery of goods, is as follows:

		30 June 2022 二零二二年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
60 days or below	60日或以下	22,154	22,244
61 to 180 days	61至180日	13,756	11,824
Over 180 days	多於180日	7,629	5,491
		43,539	39,559

14. TRADE PAYABLES

An aging analysis of the Group's trade payables as at the end of the reporting period, based on the date of receipt of goods, is as follow:

		30 June 2022 二零二二年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
60 days or below	60日或以下	15,247	12,331
61 to 180 days	61至180日	1,910	647
Over 180 days	多於180日	509	301
		17,666	13,279

13. 應收貿易賬款及票據

取決於市場及業務需求，本集團或給予客戶信貸期。本集團對結欠賬款採取嚴格之監控。管理層亦會定時檢查過期之結欠，及可能會按本集團參考市場慣例釐定之利率收取逾期利息。按董事意見，本集團沒有明顯集中信貸風險。本集團應收貿易賬款及票據之賬齡分析(以發貨日期為基準)如下：

14. 應付貿易賬款

本集團於報告期末應付貿易賬款之賬齡分析(以收貨日期為基準)如下：

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL

15. 股本

		30 June 2022 二零二二年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Authorised	法定		
<i>Ordinary shares:</i>	<i>普通股:</i>		
787,389,223 shares (31 December 2021: 787,389,223 shares) of US\$0.1 each	787,389,223股 (二零二一年十二月三十一日: 787,389,223股) 每股面值0.1美元	78,739	78,739
<i>Convertible preference shares:</i>	<i>可換股優先股:</i>		
12,610,777 shares (31 December 2021: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二一年十二月三十一日: 12,610,777股) 每股面值0.1美元	1,261	1,261
		80,000	80,000
Issued and fully paid	已發行及繳足		
<i>Ordinary shares:</i>	<i>普通股:</i>		
240,718,310 shares (31 December 2021: 240,718,310 shares) of US\$0.1 each	240,718,310股 (二零二一年十二月三十一日: 240,718,310股) 每股面值0.1美元	24,072	24,072
<i>Convertible preference shares:</i>	<i>可換股優先股:</i>		
12,610,777 shares (31 December 2021: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二一年十二月三十一日: 12,610,777股) 每股面值0.1美元	1,261	1,261
		25,333	25,333

There were no movements in the Company's issued ordinary shares and convertible preference shares during the six months ended 30 June 2022.

於截至二零二二年六月三十日止六個月內，本公司已發行普通股及可換股優先股概無變動。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL (CONTINUED)

15. 股本(續)

Notes:

The convertible preference shares are convertible into ordinary shares of the Company and are entitled to the same dividends that are declared for the ordinary shares. Convertible preference shares do not carry the right to vote in shareholders' meeting. Upon winding up, the Company's residual assets and funds are distributed to the members of the Company in the following priority:

- (i) in paying to the holders of the convertible preference shares, *pari passu* as between themselves by reference to the aggregate nominal amounts of the convertible preference shares held by them respectively, an amount equal to the aggregate of the distribution value (as defined in the bye-laws of the Company) of all the convertible preference shares held by them respectively;
- (ii) the balance of such assets shall be distributed on a *pari passu* basis among the holders of any class of shares in the capital of the Company other than the convertible preference shares and other than any shares which are not entitled to participate in such assets, by reference to the aggregate nominal amounts paid up on the shares held by them respectively; and
- (iii) the remaining balance of such assets shall belong to and be distributed on a *pari passu* basis among the holders of any class of shares including the convertible preference shares, other than any shares not entitled to participate in such assets, by reference to the aggregate nominal amounts of shares held by them respectively.

The convertible preference shares shall be non-redeemable by the Company or the holders thereof.

附註：

可換股優先股可轉換成本公司普通股及可收取與普通股持有人同等之股息。可換股優先股於股東會議不設投票權。於清盤時，本公司股東按以下次序分配本公司餘下資產及資金：

- (i) 向可換股優先股之持有人(彼等之間地位相等)參照彼等各自持有之可換股優先股面值總額支付相等於彼等各自持有之全部可換股優先股分派價值(於本公司細則中定義)總額之金額；
- (ii) 該等資產之結餘將按同等地位基準向本公司股本中任何類別股份(可換股優先股及無權參與分派該等資產之任何股份除外)之持有人(參照彼等各自持有之股份面值總額)予以分派；及
- (iii) 該等資產餘下之結餘將屬於並按同等地位基準向任何類別股份(包括可換股優先股但不包括無權參與分派該等資產之任何股份)之持有人(參照彼等各自持有之股份面值總額)予以分派。

本公司或持有人均不會對可換股優先股作出回購。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

16. CAPITAL COMMITMENTS

16. 資本承擔

The Group had the following capital commitments as at the end of the reporting period:

本集團於報告期末之資本承擔如下：

		30 June 2022 二零二二年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Contracted, but not provided for:	已簽約，但尚未作出撥備：		
Property, plant and machinery	物業、廠房及外機器	8,406	9,213

17. RELATED PARTY TRANSACTIONS

17. 關連交易

(a) Transactions with related parties

(a) 與關連人士的交易

The Group had the following transactions with related parties during the period:

本集團於期內與關連人士有以下的交易：

		Six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 US\$'000 美元千元 (Unaudited) (未經審核)	2021 二零二一年 US\$'000 美元千元 (Unaudited) (未經審核)
Sales of goods to:	銷售產品予：		
C.P. Pokphand Co., Ltd. and its subsidiaries ("CPP Group")*	卜蜂國際有限公司及其附屬公司(「卜蜂集團」)*	1,103	1,365
High Orient Enterprises Limited and its related entities, excluding CPP Group*	High Orient Enterprises Limited及其關連企業，不包括卜蜂集團*	14,383	14,077
Other related entities with same shareholders as CPG	與CPG有相同股東之其他關連企業	438	433

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

17. RELATED PARTY TRANSACTIONS (CONTINUED)

17. 關連交易(續)

(a) Transactions with related parties (continued)

(a) 與關連人士的交易(續)

Note:

附註：

Prices of goods sold to related parties were determined with reference to the cost of raw materials, procurement costs, other value added, reasonable profit margins, market demand for goods and prices offered by independent third-party suppliers of similar products. The procedures to determine the prices of products sold to related parties are the same as those used to determine the prices of products supplied to independent third party customers. Selling prices to related parties shall be no more favourable than those made available to the Group's customers which are independent third parties.

向關連人士銷售的產品售價乃按原材料成本、採購成本、其他增值、合理的利潤率、市場對該產品之需求及由獨立第三方供應商提供類似產品的價格而釐定。釐定向關連人士銷售的產品售價的程式與釐定向獨立第三方客戶供應的產品售價所用者一致。向關連人士銷售的產品售價並不遜於本集團給予獨立第三方客戶之價格。

* These related party transactions also constituted continuing connected transactions as defined in Chapter 14A of the Listing Rules.

* 該等關連人士交易也構成上市規則第14A章內定義之持續關連交易。

(b) Outstanding balances with related parties

(b) 與關連人士之間未清賬

(i) Included in the Group's trade receivables as at 30 June 2022 were aggregate amounts of US\$17,449,000 (31 December 2021: US\$17,227,000) due from related companies, arising from transactions carried out in the ordinary course of business of the Group. The balances were unsecured, bore interest at rates determined by the Group after past due and were repayable within credit periods similar to those offered by the Group to its independent third party customers.

(i) 本集團於二零二二年六月三十日之應收貿易賬款包括本集團經營日常業務交易時所產生的應收關連公司之款項合計為1,744.9萬美元(二零二一年十二月三十一日：1,722.7萬美元)。該等餘額乃無抵押、於過期後按本集團所定的利率計息及須於信貸期內償還(與本集團向獨立第三方客戶提供之利率及信貸期相若)。

(ii) Included in the Group's prepayments, deposits and other receivables as at 30 June 2022 were aggregate amounts of US\$7,166,000 (31 December 2021: US\$5,161,000) and US\$6,000 (31 December 2021: US\$13,000) due from associate and related companies respectively. The balances were unsecured, interest-free and with no fixed terms of repayment.

(ii) 本集團於二零二二年六月三十日之預付賬款、按金及其他應收賬款中，包含合計716.6萬美元(二零二一年十二月三十一日：516.1萬美元)及0.6萬美元(二零二一年十二月三十一日：1.3萬美元)分別為應收聯營公司及關連公司之款項。該餘額均無抵押、免息及無固定還款期。

(iii) Included in the Group's other payables and accruals as at 30 June 2022 were aggregate amounts of US\$41,000 (31 December 2021: US\$121,000) due to related companies. The balances were unsecured, interest-free and with no fixed terms of repayment.

(iii) 本集團於二零二二年六月三十日之其他應付賬款及預提費用中，包含合計4.1萬美元(二零二一年十二月三十一日：12.1萬美元)為應付關連公司之款項。該餘額均無抵押、免息及無固定還款期。

OTHER INFORMATION

其他資料

INTERIM DIVIDEND

The Board has resolved not to declare an interim dividend for the six months ended 30 June 2022 (six months ended 30 June 2021: nil).

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2022, the interests and short positions of the directors and chief executives of the Company in the shares and underlying shares of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") in Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules"), are set out below:

Directors' interests in shares of the Company (Long Positions)

Name of director	Capacity	Number of ordinary shares held	Approximate percentage of the issued ordinary share capital of the Company
董事名稱	身分	所持普通股股份數目	估本公司已發行普通股股本概約百分比
Mr. Thirayut Phityaisarakul 李紹慶先生	Beneficial owner 實益擁有人	410,000	0.17%
Mr. Thanakorn Seriburi 李紹祝先生	Beneficial owner 實益擁有人	625,848	0.26%

Save as disclosed above, as at 30 June 2022, none of the directors or chief executives of the Company had any interests or short positions in the shares and underlying shares of the Company or its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

中期股息

董事會決議截至二零二二年六月三十日止六個月不派付中期股息(截至二零二一年六月三十日止六個月:無)。

董事及主要行政人員持有本公司及其相聯法團的股份及相關股份的權益及淡倉

於二零二二年六月三十日,根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄,又或根據香港聯合交易所有限公司(「聯交所」)證券上市規則(「上市規則」)附錄十之上市發行人董事進行證券交易的標準守則(「標準守則」)向本公司及聯交所發出的通知,各董事及主要行政人員持有本公司及其相聯法團的股份及相關股份的權益及淡倉(按證券及期貨條例第XV部所界定者)載列如下:

董事於本公司的權益(好倉)

除上述披露者外,於二零二二年六月三十日,根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄,又或根據標準守則向本公司及聯交所發出的通知,概無任何本公司董事或主要行政人員在本公司或其相聯法團(按證券及期貨條例第XV部所界定者)的股份及相關股份中擁有任何權益或淡倉。

SUBSTANTIAL SHAREHOLDERS AND PERSONS WHO HAVE INTERESTS OR SHORT POSITIONS WHICH ARE DISCLOSEABLE UNDER THE SECURITIES AND FUTURES ORDINANCE

主要股東及根據證券及期貨條例規定須予披露擁有權益或淡倉的人士

As at 30 June 2022, the following persons (not being a director or chief executive of the Company) had the following interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

於二零二二年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，下列人士（非本公司的董事或主要行政人員）於本公司的股份及相關股份擁有的權益及淡倉如下：

Name of shareholder	Notes	Capacity	Number of shares and underlying shares held	Approximate percentage of the issued ordinary share capital of the Company
股東名稱	附註	身分	持有股份及相關股份數目	佔本公司已發行普通股股本概約百分比
			(Note 1) (附註1)	(Note 1) (附註1)
Charoen Pokphand Group Company Limited	(2)	Interest of controlled corporation 控制法團權益	127,748,147 (L)	53.1 (L)
Charoen Pokphand Foods Public Company Limited	(2)	Beneficial owner and interest of controlled corporation 實益擁有人及控制法團權益	127,748,147 (L)	53.1 (L)
CPF Investment Limited	(2)	Beneficial owner 實益擁有人	115,137,370 (L)	47.8 (L)
ITOCHU Corporation 伊藤忠商事株式會社		Beneficial owner 實益擁有人	60,179,593 (L)	25.0 (L)

Notes:

- (1) The letter "L" denotes a long position.
- (2) Charoen Pokphand Foods Public Company Limited ("CPF") held 127,748,147 shares and underlying shares of the Company, which included (i) 115,137,370 ordinary shares beneficially owned by CPF's wholly-owned subsidiary, CPF Investment Limited and (ii) 12,610,777 convertible preference shares beneficially owned by CPF. Charoen Pokphand Group Company Limited also declared interest in these shares by virtue of its shareholding interest in CPF.

Save as disclosed above, as at 30 June 2022, no person (not being a director or chief executive of the Company) had an interest or a short position in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

附註：

- (1) 「L」代表好倉。
- (2) Charoen Pokphand Foods Public Company Limited (「CPF」) 持有127,748,147股本公司股份及相關股份，其中包括(i) CPF全資附屬公司CPF Investment Limited實益擁有的115,137,370股普通股及(ii) CPF實益擁有的12,610,777股可換股優先股。Charoen Pokphand Group Company Limited亦申報因擁有CPF的股權，故同樣擁有該等股份的權益。

除上述披露者外，於二零二二年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，概無人士（非本公司董事或主要行政人員）在本公司的股份或相關股份中擁有權益或淡倉。

SHARE OPTION SCHEME

The Company adopted a share option scheme (the “Share Option Scheme”) on 18 March 2015. As at the date of this interim report, the total number of ordinary shares which may be issued upon exercise of all options to be granted under the Share Option Scheme shall not in aggregate exceed 24,071,831 shares, being 10% of the total number of ordinary shares of the Company in issue on the date of listing on 3 July 2015. As at the date of this interim report, no option had been granted, exercised, cancelled or lapsed under the Share Option Scheme.

DISCLOSURE OF DIRECTORS’ INFORMATION PURSUANT TO RULE 13.51B(1) OF THE LISTING RULES

Director’s Emolument

The total emolument of Mr. Chawalit Na Muangtoun for the six months ended 30 June 2022 was increased to US\$240,000. This amount comprised salaries, allowances and benefits in-kind in respect of his service during the period under review.

In July 2022, the Board approved the award of a discretionary bonus of US\$90,000 to Mr. Chawalit Na Muangtoun.

CORPORATE GOVERNANCE CODE

The Company is committed to maintaining strict corporate governance standards. The principles of these standards are to uphold a high standard of ethics, transparency, accountability and integrity in all aspects of business and to ensure that affairs are conducted in accordance with applicable laws and regulations.

In the opinion of the Board, the Company applied the principles and complied with the code provisions prescribed in the Corporate Governance Code as set out in Appendix 14 to the Listing Rules throughout the six months ended 30 June 2022.

DIRECTORS’ SECURITIES TRANSACTIONS

The Company has adopted the Code of Conduct for Securities Transactions, which is based on the requirements set out in the Model Code, as the code of conduct for dealings in the Company’s securities by its directors. All Directors responded to a specific enquiry by the Company and confirmed that they complied with the required standard set out in the Code of Conduct for Securities Transactions during the six months ended 30 June 2022.

購股權計劃

本公司於二零一五年三月十八日採納購股權計劃（「購股權計劃」）。於本中期報告日期，根據該購股權計劃將可授出的全部購股權獲行使時可予發行的股份總數合共不得超過24,071,831股，相當於本公司於上市日期二零一五年七月三日已發行普通股股份總數的10%。於本中期報告日期，概無根據該購股權計劃授出、行使、註銷或失效的購股權。

按上市規則第13.51B(1)條之董事資料披露

董事酬金

於截至二零二二年六月三十日止六個月，馬德壽先生之酬金總額增至24萬美元。該金額包括彼於回顧期內所提供服務相關之薪酬、津貼及非現金利益。

於二零二二年七月，董事會批准馬德壽先生獲派發9萬美元的酌情花紅。

企業管治守則

本公司致力保持嚴格的企業管治水平。其原則旨在維護公司在各業務方面均能貫徹高水平的道德、透明度、責任及誠信操守，並確保所有業務運作符合適用法律和法規。

董事會認為於二零二二年六月三十日止六個月內，本公司已應用載於上市規則附錄十四之《企業管治守則》的原則及遵守其守則條文。

董事的證券交易

本公司已採納證券交易行為守則，其乃根據標準守則所載的要求，作為其董事買賣本公司證券的行為守則。所有董事已回應本公司具體查詢並確認於截至二零二二年六月三十日止六個月內彼等遵守證券交易行為守則內所載的規定標準。

REVIEW OF INTERIM REPORT

The interim financial report for the six months ended 30 June 2022 is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. KPMG's unmodified review report is set out on pages 6 to 7 of this interim report.

The audit committee of the Company has also reviewed the interim report for the six months ended 30 June 2022.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2022, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

By Order of the Board
Thanakorn Seriburi
Director

10 August 2022

審閱中期報告

截至二零二二年六月三十日止六個月的中期財務報告為未經審核，但經畢馬威會計師事務所根據香港會計師公會頒佈的香港審閱工作準則第2410號*獨立核數師對中期財務信息的審閱*進行審閱。畢馬威會計師事務所的無修訂審閱報告已載於本中期報告的第6至7頁。

本公司審核委員會亦已審閱截至二零二二年六月三十日止六個月的中期報告。

購買、出售或贖回本公司上市證券

截至二零二二年六月三十日止六個月內，本公司或其任何附屬公司概無購買、出售或贖回任何本公司的上市證券。

承董事會命
董事
李紹祝

二零二二年八月十日

CORPORATE INFORMATION

公司資料

Chairman and Non-executive Director

Mr. Soopakij Chearavanont

董事長及非執行董事

謝吉人先生

Executive Directors

Mr. Thirayut Phityaisarakul
(Chief Executive Officer (Biochemical Division))

Mr. Thanakorn Seriburi
(Chief Executive Officer (Industrial Division))

Mr. Nopadol Chiaravanont

Mr. Chawalit Na Muangtoun

執行董事

李紹慶先生
(行政總裁 (生化業務))

李紹祝先生
(行政總裁 (工業業務))

謝杰人先生

馬德壽先生

Non-executive Director

Mr. Yoichi Ikezoe

非執行董事

池添洋一先生

Independent Non-executive Directors

Mr. Surasak Rounroengrom

Mr. Cheng Yuk Wo

Mr. Edward Ko Ming Tung

獨立非執行董事

Surasak Rounroengrom先生

鄭毓和先生

高明東先生

Audit Committee

Mr. Cheng Yuk Wo (Chairman)

Mr. Surasak Rounroengrom

Mr. Edward Ko Ming Tung

審核委員會

鄭毓和先生 (主席)

Surasak Rounroengrom先生

高明東先生

Remuneration Committee

Mr. Cheng Yuk Wo (Chairman)

Mr. Thanakorn Seriburi

Mr. Surasak Rounroengrom

Mr. Edward Ko Ming Tung

薪酬委員會

鄭毓和先生 (主席)

李紹祝先生

Surasak Rounroengrom先生

高明東先生

Nomination Committee

Mr. Soopakij Chearavanont (Chairman)

Mr. Surasak Rounroengrom

Mr. Cheng Yuk Wo

提名委員會

謝吉人先生 (主席)

Surasak Rounroengrom先生

鄭毓和先生

Corporate Governance Committee

Mr. Edward Ko Ming Tung (Chairman)

Mr. Nopadol Chiaravanont

Mr. Chawalit Na Muangtoun

企業管治委員會

高明東先生 (主席)

謝杰人先生

馬德壽先生

Company Secretary

Mr. Lau Wing Yuen

公司秘書

劉永源先生

Registered Office

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Principal Place of Business

21st Floor, Far East Finance Centre
16 Harcourt Road, Hong Kong

Auditor

KPMG
Certified Public Accountants
Public Interest Entity Auditor
registered in accordance with
the Financial Reporting Council Ordinance

Principal Bankers

Bangkok Bank
Bank of China
China Construction Bank

Share Registrars

Hong Kong
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor, Hopewell Centre
183 Queen's Road East, Wanchai, Hong Kong

Bermuda
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Share Listing

The Stock Exchange of Hong Kong Limited
Stock Code: 3839

Website

<http://www.ctei.com.hk>

註冊辦事處

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

主要營業地點

香港夏慤道16號
遠東金融中心21樓

核數師

畢馬威會計師事務所
執業會計師
於《財務匯報局條例》下
的註冊公眾利益實體核數師

主要往來銀行

盤谷銀行
中國銀行
中國建設銀行

股份過戶登記處

香港
香港中央證券登記有限公司
香港灣仔皇后大道東183號
合和中心17樓1712-1716號舖

百慕達
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

股份上市地點

香港聯合交易所有限公司
股份代號：3839

公司網站

<http://www.ctei.com.hk>



CHIA TAI ENTERPRISES INTERNATIONAL LIMITED
正大企業國際有限公司

Incorporated in Bermuda with limited liability • Stock Code : 3839
於百慕達註冊成立之有限公司 • 股份代號: 3839